M&A Deal Summary

Teva Pharmaceutical Industries Acquires Cephalon

On October 14, 2011, Teva Pharmaceutical Industries acquired life science company Cephalon for 6.8B USD

Acquisition Highlights
  • This is Teva Pharmaceutical Industries’ 13th transaction in the Life Science sector.
  • This is Teva Pharmaceutical Industries’ 4th largest (disclosed) transaction.
  • This is Teva Pharmaceutical Industries’ 7th transaction in the United States.
  • This is Teva Pharmaceutical Industries’ 1st transaction in Pennsylvania.

M&A Deal Summary
Date 2011-10-14
Target Cephalon
Sector Life Science
Buyer(s) Teva Pharmaceutical Industries
Deal Type Add-on Acquisition
Deal Value 6.8B USD
Advisor(s) BofA Securities
Deutsche Bank Corporate & Investment Banking (Financial)
Skadden, Arps, Slate, Meagher & Flom (Legal)

Target

Cephalon

Frazer, Pennsylvania, United States
Cephalon is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world. Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients in several therapeutic areas.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Teva Pharmaceutical Industries

Tel Aviv, Israel
Category Company
Founded 1901
Sector Life Science
Employees35,001
Revenue 15.8B USD (2023)
DESCRIPTION

Teva Pharmaceutical Industries is a provider of pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Teva Pharmaceutical Industries was founded in 1901 and is based in Tel Aviv, Israel.

DEAL STATS #
Overall 14 of 23
Sector (Life Science) 13 of 20
Type (Add-on Acquisition) 12 of 19
State (Pennsylvania) 1 of 2
Country (United States) 7 of 15
Year (2011) 2 of 2
Size (of disclosed) 4 of 14
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2011-01-26 Corporación Infarmasa SA

Lima, Peru

Corporación Infarmasa SA manufactures and markets branded and unbranded generic drugs, primarily corticosteroids, antihistamines, analgesics and antibiotics, and has of over 600 registered products, of which over 500 are currently marketed.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2013-06-17 MicroDose Therapeutx

Monmouth Junction, New Jersey, United States

MicroDose Therapeutx is a private pharmaceutical company focused on developing proprietary pulmonary and oral products that address large unmet market opportunities, and on dry powder inhalation and combination oral dosage delivery platforms.

Buy $40M
Mergr

Product

Company

Legal